Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Status Status +17.90%
#3 Ontology Gas Ontology Gas +12.46%
#4 GoPlus Security GoPlus Security +11.51%
#5 DMT-NAT DMT-NAT +9.70%
#6 Fake World Assets Fake World Assets +8.34%
#7 Provenance Blockchain Provenance Blockchain +6.75%
#8 Bedrock Bedrock +6.48%
#9 Janction Janction +6.24%
#10 Ontology Ontology +5.54%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
PJSC Pharmsynthez PJSC Pharmsynthez

PJSC Pharmsynthez

LIFE
Kedudukan dalam Saham #34086
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation,... PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
Harga Saham
$0.02082992
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$6.27M
Perubahan (1 hari)
-3.31%
Perubahan (1 tahun)
-51.62%
Negara
RU
Perdagangan PJSC Pharmsynthez (LIFE)

Kategori

Healthcare
Pendapatan untuk PJSC Pharmsynthez (LIFE)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini PJSC Pharmsynthez, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi PJSC Pharmsynthez dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE